NeuCeno – Alkem’s Antiseizure Drug for Partial Onset Seizures in Adults

The pharmaceutical company Alkem Laboratories has launched an antiseizure drug called NeuCeno that comprises cenobamate and is meant for adults affected by partial onset seizures. This is the first time that this medicine is being launched by the pharmaceutical company in India. 

Invest in Indian Markets and Unlock Future Potential With 5paisa!

Open Account Now

The news regarding the launch of the drug was given out by the company on September 16. The drug can be taken orally once a day and is available in six different doses, which are 12.5 mg, 25 mg, 50 mg, 100 mg, 150 mg and 200 mg tablets. 

This launch provides yet another alternative to treat epilepsy, a disease that is estimated by Alkem to affect around 9.4 million people in India. 

Cenobamate entered the Indian market 

NeuCeno contains cenobamate, a newly approved medication for the treatment of partial-onset seizures in adult patients. 

As per information obtained from Alkem, cenobamate functions based on two modes of action. Firstly, it is the selective inhibitor of the persistent sodium currents that are responsible for repetitive neuronal firing; secondly, it is the positive modulator of the GABA-A receptor. 

The company mentioned a number of randomized clinical trials carried out among adults with uncontrolled focal seizures in conjunction with other anti-seizure medications. 

During the clinical trials, the adjunctive use of cenobamate resulted in a 78% decrease in the frequency of seizures and 30% of patients without seizures during the maintenance period. 

It is necessary to note that this information refers to the results of the mentioned clinical trials and does not necessarily reflect outcomes for all patients. 

Epilepsy treatment gap in India identified by Alkem 

The introduction of the new medicine comes against a backdrop of significant epilepsy prevalence in India. According to information provided by the company, 9.4 million people suffer from the condition in India. 

Although there are several anti-seizure medicines on the market, uncontrolled seizures still occur in some patients. 

Alkem launches more chronic therapy product range 

Alkem Laboratories is an entity that deals with products in the acute and chronic therapies range. Its current focus areas include anti-infectives, gastrointestinal therapy, pain therapy and supplements, whereas its chronic therapy includes diabetes, neurology, cardiology, dermatology and urology. 

The firm refers to itself as one of the six largest pharmaceutical firms in the Indian market. 

Alkem has 20 manufacturing plants along with R&D centers located in India and the US. It is involved in generic formulations, APIs and biosimilars. 

Internationally, the company has operations in the US, Latin America, Australia and several Asian markets. 

Through NeuCeno, Alkem now introduces Cenobamate in India for adults suffering from partial onset seizures with the drug being available in six dose strengths for once daily oral intake.